34 completed. 34 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 34 | Completed 34 |
| Phase 2 | 16 | Completed 16 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment Mesenchymal Stem Cells from Wharton´s jelly - Systemic Sclerosis Pulmonary, Pulmonary Hypertension | Phase 1 / Phase 2 | Completed | Fundación Neumologica Colombiana | 1 | 2024-05-15 | 2026-04-21 |
| A Study of MK-2225 in Healthy Participants (MK-2225-003) MK-2225, Placebo - Systemic Sclerosis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 32 | 2023-11-21 | 2025-07-29 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis RO7303509, Placebo - Systemic Sclerosis | Phase 1 | Completed | Genentech, Inc. | 56 | 2023-01-16 | 2025-07-20 |
| Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects CM-101, Placebo - Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | ChemomAb Ltd. | 8 | 2019-03-05 | 2023-09-14 |
| Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis AVID200 - Scleroderma, Diffuse | Phase 1 | Completed | Bristol-Myers Squibb | 9 | 2019-01-01 | 2024-11-19 |
| A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis VIB7734, Placebo - Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 1 | Completed | Amgen | 31 | 2018-12-13 | 2024-12-13 |
| A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) Microgynon, Nintedanib - Scleroderma, Systemic | Phase 1 | Completed | Boehringer Ingelheim | 17 | 2018-11-08 | 2020-11-09 |
| Gut Microbiota Transplantation in Systemic Sclerosis Anaerobically Cultivated Human Intestinal Microbiota, Anaerobically Cultivated medium - Scleroderma, Systemic | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 10 | 2018-01-18 | 2019-03-13 |
| A Study of KHK4827 in Patients With Systemic Sclerosis KHK4827 - Systemic Sclerosis | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 8 | 2017-10-06 | 2025-07-11 |
| Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Tofacitinib, Placebo Oral Tablet - Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | University of Michigan | 15 | 2017-09-25 | 2020-05-08 |
| Brentuximab Vedotin for Systemic Sclerosis Brentuximab Vedotin, Placebo - Diffuse Cutaneous Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 17 | 2017-09-20 | 2026-05-05 |
| Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study Iontophoresis of treprostinil, Iontophoresis of placebo - Scleroderma, Systemic | Phase 1 / Phase 2 | Completed | University Hospital, Grenoble | 18 | 2017-06-20 | 2020-04-10 |
| Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma dabigatran etexilate - Scleroderma, Interstitial Lung Disease | Phase 1 | Completed | Medical University of South Carolina | 15 | 2016-02-01 | 2018-07-13 |
| Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial C-82 Topical Gel, 1%, C-82 Topical Gel, Placebo - Systemic Scleroderma | Phase 1 / Phase 2 | Completed | Prism Pharma Co., Ltd. | 17 | 2015-06-01 | 2017-08-17 |
| A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects GSK2330811, Placebo - Scleroderma, Systemic | Phase 1 | Completed | GlaxoSmithKline | 41 | 2015-04-21 | 2017-05-15 |
| Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS - SYSTEMIC SCLERODERMA, ALLOGENEIC MESENCHYMAL STEM CELLS | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 20 | 2014-05-06 | 2024-05-01 |
| Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis Omeprazole 20mg - Systemic Sclerosis, Gastroesophageal Reflux | Phase 1 | Completed | Khon Kaen University | 250 | 2013-05-01 | 2018-06-21 |
| IL1-TRAP, Rilonacept, in Systemic Sclerosis Rilonacept, Placebo - Scleroderma, Systemic Sclerosis | Phase 1 / Phase 2 | Completed | Boston University | 24 | 2011-12-01 | 2018-05-01 |
| Fresolimumab In Systemic Sclerosis Fresolimumab - Diffuse Systemic Sclerosis | Phase 1 | Completed | Boston University | 18 | 2011-01-01 | 2014-07-16 |
| A Study of the Safety and Tolerability of MEDI-551 in Scleroderma MEDI-551, Placebo - Scleroderma | Phase 1 | Completed | MedImmune LLC | 50 | 2010-03-01 | 2014-11-13 |
Showing 20 of 34. Sign in to see all of them.
Scleroderma, Diffuse (17) · Dermatomyositis (2) · Lupus Erythematosus, Systemic (2) · Acne Keloid (1) · Arthritis (1) · Arthritis, Juvenile (1) · Autoimmune Diseases (1) · Cholangitis, Sclerosing (1) · Cicatrix (1) · Communicable Diseases (1) · Connective Tissue Diseases (1) · Gastroesophageal Reflux (1) · Granuloma Annulare (1) · Hypertension, Pulmonary (1)
Skin Diseases (34) · Skin and Connective Tissue Diseases (34) · Connective Tissue Diseases (33) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Digestive System Diseases (2) · Fibrosis (2) · Joint Diseases (2) · Lung Diseases (2) · Muscular Diseases (2) · Musculoskeletal Diseases (2) · Myositis (2) · Nervous System Diseases (2) · Neuromuscular Diseases (2)
Imatinib Mesylate (2) · Mycophenolic Acid (2) · Stem Cell Transplantation (2) · Whole-Body Irradiation (2) · Abatacept (1) · Biopsy (1) · Bone Marrow Transplantation (1) · Brentuximab Vedotin (1) · Cyclophosphamide (1) · Dabigatran (1) · Dasatinib (1) · Flow Cytometry (1) · Granulocyte Colony-Stimulating Factor (1) · Leukapheresis (1) · Mesna (1)
Boston University (3) · Bristol-Myers Squibb (2) · Fred Hutchinson Cancer Center (2) · MedImmune LLC (2) · Stanford University (2) · University of California, Los Angeles (2) · University of Michigan (2) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · Boehringer Ingelheim (1) · ChemomAb Ltd. (1) · Fundación Neumologica Colombiana (1) · Genentech, Inc. (1) · Genzyme, a Sanofi Company (1)
United States (24) · France (4) · Spain (4) · United Kingdom (3) · Belgium (2) · Israel (2) · Poland (2) · Portugal (2) · Argentina (1) · Canada (1) · Colombia (1) · Germany (1) · Japan (1) · Netherlands (1) · Norway (1)
Robert Lafyatis, MD (4) · Ann Woolfrey (1) · Anna-Maria Hoffmann-Vold, PhD (1) · Arnon Aharon, MD (1) · Carol A. Wallace, MD (1) · Daniel E. Furst, MD (1) · David Fox, MD (1) · Dinesh Khanna, MD (1) · Dinesh Khanna, MD, MSc (1) · Eliza Farmer Chakravarty (1)
PMID 19180499, PMID 19950289, PMID 21769849, PMID 23597147, PMID 24559157, PMID 26071192, PMID 26098215, PMID 27267753, PMID 29121645, PMID 30277862, PMID 34664183, PMID 35943798, PMID 36688692, PMID 36928395, PMID 36997069, PMID 38501358, PMID 40013233
2018 (2), R01AI041721 (1), R21AR065089 (1), UM1AI109565 (1)